You are here
Arisan Therapeutics, Inc.
http://www.arisanthera.com
UEI: PYRKTQPNVJZ8
# of Employees: 8
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Evaluation of ARN-75039 for dual efficacy against both parenteral and aerosolized Lassa virus infection in a guinea pig model.
Amount: $269,361.72Arenaviruses comprise a diverse group of Old (Africa) and New World (Americas) species. Several species are associated with hemorrhagic fever (HF) with case-fatality rates as high as 30%. Arenavirus i ...
SBIRPhase II2021Department of Defense Office for Chemical and Biological Defense -
Optimization of a broad-spectrum Ebolavirus cell entry inhibitor chemical series as a countermeasure for parental and aerosol routes of infection
Amount: $587,720.40Ebolavirus species including Zaire (EBOV), Sudan (SUDV) and Bundibugyo (BDBV) are responsible for severe hemorrhagic fever outbreaks with high case fatalities in Africa [1,2]. Outbreaks of EBOV in the ...
SBIRPhase II2021Department of Defense Office for Chemical and Biological Defense -
Development of Small Molecule Therapeutics for Emerging Viral Agents
Amount: $96,111.02Arenaviruses comprise a diverse group of Old (Africa) and New World (Americas) species. Several species are associated with hemorrhagic fever (HF) with case-fatality rates as high as 30%. Arenaviruses ...
SBIRPhase I2020Department of Defense Office for Chemical and Biological Defense -
Development of Small Molecule Therapeutics for Emerging Viral Agents
Amount: $167,442.00Ebolavirus species including Zaire (EBOV), Sudan (SUDV) and Bundibugyo (BDBV) are responsible for severe hemorrhagic fever outbreaks with high case fatalities in Africa. Weaponized pathogens present a ...
SBIRPhase I2020Department of Defense Office for Chemical and Biological Defense -
Pre-IND Development of an Arenavirus Antiviral
Amount: $2,997,148.00Summary Arenaviruses comprise a diverse family. Several species are associated with severe arenaviral hemorrhagic fever (AVHF) in humans that exhibit case-fatality rates as high as 30%. Human infectio ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Development of a Highly Sensitive Quantitative Rapid Digital LSPR Diagnostic for Acute Dengue and Zika Virus Infection
Amount: $2,000,000.00Project Summary Ideally, the utilization of point-of-care (POC) diagnostics to facilitate early clinical decision-making for infectious disease agents requires compatibility in both developing and dev ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Optimization of Ebola Virus Entry Inhibitors
Amount: $650,000.00Infection by several Ebola virus species is associated with severe viral hemorrhagic feverVHFin humansTo datesignificant Ebola virus outbreaks in central and western Africa have been associated with t ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Arenavirus Antiviral Lead Optimization
Amount: $3,000,000.00DESCRIPTION provided by applicant Arenaviruses comprise a diverse family Several species are associated with severe arenaviral hemorrhagic fever AVHF in humans that exhibit case fatality rates a ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases
Amount: $300,000.00Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastruc ...
STTRPhase I2016Department of Health and Human Services National Institutes of Health -
Ebola Virus Entry Inhibitors
Amount: $300,000.00DESCRIPTION provided by applicant Several Ebola virus species have been associated with severe viral hemorrhagic fevers VHF in humans Human infection typically occurs through contact with blood ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health
